Immunitybio Inc (IBRX) - Total Assets
Based on the latest financial reports, Immunitybio Inc (IBRX) holds total assets worth $518.99 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore cash flow to debt ratio of Immunitybio Inc to assess how comfortably operating cash covers total debt obligations.
Immunitybio Inc - Total Assets Trend (2013–2024)
This chart illustrates how Immunitybio Inc's total assets have evolved over time, based on quarterly financial data. See IBRX total equity for net asset value and shareholders' equity analysis.
Immunitybio Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Immunitybio Inc's total assets of $518.99 Million consist of 48.2% current assets and 51.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 37.5% |
| Accounts Receivable | $2.65 Million | 0.7% |
| Inventory | $8.27 Million | 2.2% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $15.93 Million | 4.2% |
| Goodwill | $910.00K | 0.2% |
Asset Composition Trend (2013–2024)
This chart illustrates how Immunitybio Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Immunitybio Inc market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Immunitybio Inc's current assets represent 48.2% of total assets in 2024, an increase from 46.5% in 2013.
- Cash Position: Cash and equivalents constituted 37.5% of total assets in 2024, up from 16.6% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 4.0% of total assets, a decrease from 41.0% in 2013.
- Asset Diversification: The largest asset category is intangible assets at 4.2% of total assets.
Immunitybio Inc Competitors by Total Assets
Key competitors of Immunitybio Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Akero Therapeutics Inc
NASDAQ:AKRO
|
USA | $1.01 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Zealand Pharma A/S
CO:ZEAL
|
Denmark | Dkr16.46 Billion |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
|
China | CN¥6.66 Billion |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
Immunitybio Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.77 | 2.68 | 1.64 |
| Quick Ratio | 5.65 | 2.64 | 1.64 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $272.36 Million | $102.19 Million | $43.58 Million |
Immunitybio Inc - Advanced Valuation Insights
This section examines the relationship between Immunitybio Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 15.56 |
| Asset Growth Rate (YoY) | -24.1% |
| Total Assets | $382.93 Million |
| Market Capitalization | $5.96 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Immunitybio Inc's assets at a significant premium (15.56x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Immunitybio Inc's assets decreased by 24.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Immunitybio Inc (2013–2024)
The table below shows the annual total assets of Immunitybio Inc from 2013 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $382.93 Million | -24.09% |
| 2023-12-31 | $504.45 Million | +39.21% |
| 2022-12-31 | $362.36 Million | -22.72% |
| 2021-12-31 | $468.91 Million | +111.81% |
| 2020-12-31 | $221.38 Million | +54.68% |
| 2019-12-31 | $143.12 Million | -21.34% |
| 2018-12-31 | $181.95 Million | -27.35% |
| 2017-12-31 | $250.44 Million | -21.12% |
| 2016-12-31 | $317.50 Million | -13.45% |
| 2015-12-31 | $366.85 Million | +503.09% |
| 2014-12-31 | $60.83 Million | +2792.44% |
| 2013-12-31 | $2.10 Million | -- |
About Immunitybio Inc
ImmunityBio, Inc., a commercial stage biotechnology company, develops next-generation therapies that bolster the natural immune systems to defeat cancers and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therap… Read more